
## CLAIMS


What is claimed is:

1. A compound of Formula **I**:



**I**,

or a pharmaceutically acceptable salt thereof; wherein

T is  ;

X is O;

Y is O;

Z is a bond;

$R^1$ is $C_{2-4}$ alkynyl;

$R^2$ is $C_{1-4}$ alkyl;

$R^3$ is hydrogen, alkyl, alkynyl, heteroarylalkyl, heterocyclyl, or heterocyclylalkyl, wherein $R^3$ is optionally substituted with $-NR^aR^b$ or alkyl;

$R^4$ and $R^5$ are hydrogen;

each occurrence of $R^6$ is, independently, F, Cl, or Br;

G is hydrogen;

m is 1 or 2; and

each occurrence of $R^a$ and $R^b$ is, independently, hydrogen, acyl, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, heterocyclyl, $C(O)OC_{1-6}$ alkyl, $C(O)C_{1-6}$ alkyl, or $R^a$ and $R^b$ together with the atoms to which they are attached form a heterocyclyl ring.

2. A pharmaceutical composition comprising the compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. The compound of claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, for use in therapy.

4. Use of the compound of claim 1, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 2, in the manufacture of a medicament for treating a disease or condition.

5. The use of claim 4, wherein the disease or condition is selected from the group consisting of fibrotic skin disorders, lung disease, heart disease, kidney disease, and cirrhosis of the liver.

6. The use of claim 5, wherein the disease or condition is kidney disease.

7. The use of claim 6, wherein the kidney disease is progressive kidney disease, glomerulonephritis, diabetic kidney disease, diabetic nephropathy, systemic lupus, primary glomerulonephritis, membranous nephropathy, focal segmental glomerulosclerosis, membranoproliferative glomerulonephritis, diffuse proliferative glomerulonephritis, membranous focal segmental glomerulosclerosis, secondary glomerulonephritis, or ischemic nephropathy.

8. The use of claim 6, wherein the kidney disease is focal segmental glomerulosclerosis.